Please visit answersincme.com/GPV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses bispecific antibodies in the current treatment landscape of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of relapsed/refractory (R/R) multiple myeloma (MM); Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated R/R MM; and Describe strategies to optimize outcomes with bispecific antibodies for the treatment of R/R MM. This activity is intended for US healthcare professionals only.
Fler avsnitt av CME in Minutes: Education in Primary Care
Visa alla avsnitt av CME in Minutes: Education in Primary CareCME in Minutes: Education in Primary Care med Answers in CME finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
